Welcome to our dedicated page for Bellus Health news (Ticker: BLU), a resource for investors and traders seeking the latest updates and insights on Bellus Health stock.
BELLUS Health Inc. (BLU) is a clinical-stage biopharmaceutical company advancing BLU-5937, a highly selective P2X3 antagonist for chronic cough treatment. This page provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated news collection offers timely access to press releases about Phase III trial progress, FDA communications, and research collaborations. Track updates on BLU-5937's potential to address unmet needs for 2.7M+ chronic cough patients in the US who lack effective therapies.
Key coverage areas include clinical data readouts, intellectual property developments, and corporate financial updates. All content is sourced from official company communications and verified industry reports.
Bookmark this page for structured tracking of BELLUS Health's progress in bringing novel therapeutics to market. Check regularly for updates on pivotal developments affecting both patient care and investment considerations.
BELLUS Health (Nasdaq: BLU) announced Ramzi Benamar as its new Chief Financial Officer. With over 20 years in the biopharmaceutical sector, Benamar previously served as CFO at DBV Technologies and held senior roles in financial planning at Spark Therapeutics and major firms like Merck and Johnson & Johnson. His expertise is expected to enhance BELLUS's strategy as it advances its clinical pipeline, notably the promising drug candidate BLU-5937 for treating chronic cough. The appointment aims to strengthen the company's financial leadership amid upcoming data readouts.
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) announced that its President and CEO, Roberto Bellini, will participate in a fireside chat at the Evercore ISI 3rd Annual Virtual HealthCONx Conference on December 3, 2020, at 10:30 a.m. EST. The event will focus on the company's development of novel therapeutics for chronic cough and hypersensitization-related disorders, particularly the product candidate BLU-5937. Chronic cough affects around 26 million adults in the U.S., with limited treatment options available.
BELLUS Health (Nasdaq:BLU) announced its Q3 2020 financial results, reporting a net loss of US$5.7 million (US$0.09 per share), an improvement from US$6.5 million (US$0.14 per share) in Q3 2019. The company completed a US$40.3 million share offering in October, increasing total cash and equivalents to US$107 million. BELLUS is set to initiate the Phase 2b SOOTHE trial for BLU-5937 in refractory chronic cough and the BLUEPRINT trial for chronic pruritus in Q4 2020, with topline results expected in 2021.
BELLUS Health, a clinical-stage biopharmaceutical company, announced that CEO Roberto Bellini will join a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 4:25 p.m. GMT. Investors can access the live webcast on the Company's website and find an archived version post-event. BELLUS Health is developing BLU-5937, targeting chronic cough and chronic pruritus, conditions affecting millions of adults in the U.S. with significant impacts on quality of life.
BELLUS Health (NASDAQ: BLU) has completed its underwritten public offering of 17,888,889 common shares at US$2.25 per share, raising approximately US$40 million. The funds will be used for research and development, administrative expenses, and working capital. The company’s shares are dual-listed on Nasdaq and TSX. Insiders, including Chairman Dr. Francesco Bellini, purchased 1.55% of the offering, which is exempt from formal valuation requirements. The offering is part of the company’s efforts to advance its therapeutics for chronic cough and other disorders.
BELLUS Health has announced a public offering of 15,555,556 common shares at a price of US$2.25 per share, with expected closing on October 22, 2020. The offering is underwritten by Jefferies, Evercore ISI, and LifeSci Capital. An additional 2,333,333 shares may be purchased by underwriters within 30 days. Proceeds from the offering will primarily fund research and development, general administrative expenses, working capital, and corporate purposes. The shares are listed on TSX and Nasdaq under the symbol 'BLU'.
BELLUS Health (BLU) has filed a preliminary prospectus supplement for a public offering of common shares. The offering aims to raise funds for research and development, general administrative expenses, and working capital needs. It includes a 30-day underwriter option for an additional 15% share purchase. Pricing will be determined based on market conditions, and it is subject to TSX approval. Jefferies and Evercore ISI are managing the offering.
FAQ
What is the market cap of Bellus Health (BLU)?
